VIVS VivoSim Labs, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1497253 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.6%
TTM net income YoY-417.8%
TTM EPS YoY-768.6%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,897.8%
Net margin-7,605.9%
FCF margin-7,618.5%
EBITDA margin-8,771.9%
Returns
ROE-143.5%
ROA-104.7%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.50x
Interest coverage-1,001.00x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue63.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2025Q32025-12-31 | 2025Q22025-09-30 | 2025Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $51,000 | $18,000 | $40,000 | $26,000 | $28,000 | $37,000 | $51,000 | $24,000 |
| Cost of revenue | $56,000 | — | $0 | $0 | $0 | $0 | $0 | $2,000 |
| Gross profit | -$5,000 | — | $40,000 | $26,000 | $28,000 | $37,000 | $51,000 | $22,000 |
| R&D expense | $1.10M | $1.13M | $1.12M | $1.14M | $923,000 | $1.00M | $859,000 | $1.78M |
| SG&A expense | $2.21M | $1.65M | $2.10M | $1.64M | $1.74M | $1.95M | $2.35M | $1.71M |
| Operating income | -$3.32M | -$2.76M | -$3.19M | -$2.75M | -$2.63M | -$2.92M | -$3.15M | -$3.47M |
| Interest expense | $0 | $4,000 | $4,000 | $4,000 | $0 | $4,000 | $5,000 | $5,000 |
| Income tax | $0 | $3,000 | $0 | $0 | $2,000 | $0 | $0 | $0 |
| Net income | -$475,000 | -$1.34M | -$5.76M | -$2.69M | -$2.54M | -$2.84M | $6.85M | -$3.45M |
| EBITDA | -$3.28M | -$2.72M | -$3.14M | -$2.70M | -$2.58M | -$2.85M | -$3.09M | -$3.40M |
| EPS (basic) | -0.03 | -0.25 | — | -1.03 | -0.98 | -1.14 | — | -2.28 |
| EPS (diluted) | -0.03 | -0.25 | — | -1.03 | -0.98 | -1.14 | — | -2.28 |
| Weighted avg. shares (diluted) | 16.45M | 5.24M | — | 2.61M | 2.60M | 2.50M | — | 1.50M |
| Balance sheet | ||||||||
| Cash & equivalents | $8.56M | $1.67M | $5.02M | $4.29M | $6.68M | $9.05M | $11.31M | $1.16M |
| Receivables | $56,000 | $29,000 | $32,000 | $33,000 | $32,000 | $32,000 | $30,000 | $26,000 |
| Inventory | $30,000 | — | $0 | — | — | — | $0 | $0 |
| Current assets | $9.40M | $3.23M | $6.63M | $6.04M | $7.59M | $9.68M | $12.13M | $2.10M |
| PP&E, net | $217,000 | $189,000 | $206,000 | $248,000 | $300,000 | $359,000 | $419,000 | $479,000 |
| Total assets | $9.92M | $3.85M | $7.39M | $6.96M | $9.69M | $11.98M | $14.65M | $3.84M |
| Current liabilities | $2.68M | $1.89M | $2.79M | $2.48M | $2.45M | $2.14M | $3.74M | $2.94M |
| Total liabilities | $2.68M | $6.19M | $8.48M | $2.52M | $2.62M | $2.44M | $4.16M | $3.48M |
| Shareholders' equity | $7.24M | -$2.35M | -$1.10M | $4.44M | $7.07M | $9.54M | $10.49M | $364,000 |
| Shares outstanding | 18.07M | 3.19M | 2.89M | 2.61M | 2.61M | 2.60M | 1.90M | 17.13M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.48M | -$3.21M | -$2.24M | -$2.27M | -$2.38M | -$3.94M | -$2.04M | -$1.80M |
| Capital expenditure | $62,000 | $23,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$2.54M | -$3.24M | -$2.24M | -$2.27M | -$2.38M | -$3.94M | -$2.04M | -$1.80M |
| Investing cash flow | $5.95M | -$23,000 | $94,000 | $0 | $0 | $0 | $9.00M | $4,000 |
| Financing cash flow | $3.42M | -$118,000 | $2.88M | -$118,000 | $0 | $1.68M | $3.19M | -$216,000 |
| Depreciation & amortization | $35,000 | $40,000 | $43,000 | $52,000 | $59,000 | $61,000 | $61,000 | $67,000 |
| Stock-based compensation | $235,000 | $91,000 | $86,000 | $67,000 | $72,000 | $78,000 | $91,000 | $130,000 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.